Insulet Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PODD research report →
Companywww.insulet.com
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia.
- CEO
- Ashley A. McEvoy
- IPO
- 2007
- Employees
- 5,400
- HQ
- Acton, MA, US
Price Chart
Valuation
- Market Cap
- $10.85B
- P/E
- 36.19
- P/S
- 3.74
- P/B
- 8.41
- EV/EBITDA
- 20.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 71.01%
- Op Margin
- 17.48%
- Net Margin
- 10.44%
- ROE
- 21.38%
- ROIC
- 16.39%
Growth & Income
- Revenue
- $2.71B · 30.73%
- Net Income
- $247.10M · -40.93%
- EPS
- $3.51 · -41.21%
- Op Income
- $473.80M
- FCF YoY
- 23.67%
Performance & Tape
- 52W High
- $354.88
- 52W Low
- $145.59
- 50D MA
- $194.55
- 200D MA
- $274.13
- Beta
- 1.20
- Avg Volume
- 1.21M
Get TickerSpark's AI analysis on PODD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | McEvoy Ashley | other | 1,411 |
| Apr 1, 26 | Panos Michael | other | 7,255 |
| Apr 1, 26 | Panos Michael | other | 2,777 |
| Mar 30, 26 | Panos Michael | other | 0 |
| Mar 31, 26 | Huffines Robert Luther | other | 111 |
| Feb 27, 26 | Singh Prem | other | 207 |
| Feb 27, 26 | Singh Prem | other | 62 |
| Feb 27, 26 | Cousin Laetitia | other | 200 |
| Feb 27, 26 | Cousin Laetitia | other | 53 |
| Feb 27, 26 | Budden Lauren | other | 119 |
Our PODD Coverage
View all →
Insulet Corporation (PODD) drops after deep earnings analysis
Insulet beat on EPS and revenue, lifted full-year guidance, and still saw PODD drop sharply. This deep-dive looks beyond the headline beat to examine Omnipod growth, margin expansion, guidance nuance, and why investors focused on valuation and reaction rather than the strong quarter.
Insulet (PODD): Growth Runway Still Justifies a Buy
Insulet is compounding revenue, margins, and free cash flow while expanding Omnipod’s reach in type 1 and type 2 diabetes. The stock still trades at a premium, but the growth runway and product leadership remain compelling.
Insulet Corporation (PODD) drops after earnings beats
Insulet Corporation (PODD) drops 6.3% even after earnings beats, as investors react to the latest quarterly results and outlook.
Want a deeper read on PODD?
Generate a full analyst-grade report — bull / bear case, price targets, valuation depth, and a complete financial breakdown.